Richard Goodman

Richard Goodman is an Associate Research Scientist in the Department of Neuroscience at Yale School of Medicine. He holds advanced degrees from MIT (B.S. Chemistry, 1970) and the University of Pennsylvania (M.D. & Ph.D., 1976). His clinical training included internal medicine at Tufts-New England Medical Center and endocrinology fellowships at NEMC and Massachusetts General Hospital, where he co-discovered GLP-1—a foundational compound for weight-loss drugs like Ozempic. Goodman served as founding director of the Molecular Medicine division at NEMC, fostering an environment where four faculty members later joined the National Academy of Sciences. He led the Vollum Institute for 27 years and was elected to the National Academy of Sciences (2002) and National Institute of Medicine (2005).

His research focuses on transcriptional regulation, metabolic pathways, and biosensor technologies. Key contributions include defining the CREB regulon, elucidating NAD⁺ dynamics, and developing fluorescent biosensors for cellular processes. Goodman’s work bridges basic science and clinical applications, particularly in endocrinology and neurobiology.

Notable collaborations include studies with Kevin Sevarino on somatostatin gene regulation and recent projects on glycolytic dynamics. Awards include Yale’s Distinguished Graduate Award (2013). His leadership has driven interdisciplinary research programs, emphasizing translational outcomes in health sciences.